NCT05215379已完成2 期
Multicenter Prospective Randomized Clinical Trial of Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 1
- 主要终点
- The rate of cCR
研究概览
简要总结
At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ultra low rectal cancer patients evaluated by multidisciplinary team to perform APR
- •Patients who have a strong desire to preserve the anus and are willing to accept neoadjuvant treatment
- •18 years old ≤ age ≤ 75 years old, no gender limit;
- •Colonoscopy, intracavitary ultrasound and pelvic high-resolution MRI (or enhanced CT) were diagnosed as extremely low rectal cancer within 5 cm from the lower edge of the tumor to the anal edge. The baseline clinical stage is T1-3aN0-1M0, and the size of the tumor <1/2 circle;
- •Histopathological diagnosis of rectal adenocarcinoma; tumor biopsy immunohistochemistry showed pMMR, that is, MSH1, MSH2, MSH6 and PMS2 four proteins are positive, or genetic testing suggests MSI-L or MSS.
- •The patient has good compliance and can come to the hospital for reexamination as required;
- •ECOG physical status score 0-1 points;
- •Have not received anti-tumor and immunotherapy before being selected;
- •8. Laboratory inspections must meet the following standards: i. White blood cell count ≥3.5×109/L, absolute neutrophil count ≥1.8×109/L, platelet count ≥100×10^9/L, hemoglobin ≥100g/L; ii. INR≤1.5, and APTT≤1.5 times the upper limit of normal value or partial prothrombin time (PTT)≤1.5 times the upper limit of normal value; iii. Total bilirubin≤1.25 times the upper limit of normal; ALT and AST≤5 times the upper limit of normal; iv. 24h creatinine clearance rate ≥50mL/min or blood creatinine ≤1.5 times the upper limit of normal.
- •Voluntarily sign the informed consent form;
排除标准
- •History of other malignant diseases in the past 5 years;
- •Patients with metastases ;
- •Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who need emergency surgery;
- •Those who are known to be allergic to capecitabine, oxaliplatin, PD-1 monoclonal antibody and other drugs;
- •Patients with poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous adenocarcinoma;
- •The patient is accompanied by any unstable systemic diseases, including but not limited to: severe infection, uncontrolled diabetes, hypertension that cannot be controlled by drugs, unstable angina, cerebrovascular accident or transient cerebral ischemia, myocardium Infarction, congestive heart failure, severe arrhythmia requiring medication, liver, kidney or metabolic diseases; diseases that affect the life of the patient.
- •The patient's accompanying diseases (such as mental illness, etc.) or conditions (such as alcohol or drug abuse, etc.) will increase the patient's risk of receiving experimental drug treatment or affect the patient's compliance with the trial requirements, or may confuse the research results;
- •Within 30 days before screening, the patient has received any other experimental drug treatment or participated in another interventional clinical trial;
- •Women who are pregnant or breastfeeding or who intend to become pregnant or breastfeeding during the study period; men or women who are unwilling to take effective contraceptive measures;
- •The investigator judges that the patient is not suitable to participate in other situations such as the clinical trial.
研究组 & 干预措施
neoadjuvant chemoradiation therapy
Other
neoadjuvant chemoradiation therapy
干预措施: Control (Other)
neoadjuvant chemoradiation therapy +immunotherapy
Experimental
neoadjuvant chemoradiation therapy +immunotherapy
干预措施: xintilimab injection (Drug)
结局指标
主要结局
The rate of cCR
时间窗: 2 years
Rate of patients who achieve clinical complete response
次要结局
- The rate of organ preservation(2 years)
- The rate of anus preservation(2 years)
- pCR rate(2 years)
- Disease free survival(DFS)(2 years)
- Quality of life(2 years)
- overall survival(OS)(2 years)
研究者
Wei Zhang
Chief physician, professor
Changhai Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Comparison study on the effect of capsular tension ring according to the number of intraocular lens hapticsKCT0003922Korea University Ansan Hospital40
招募中
不适用
Clinical prospective study to investigate efficacy and safety of immune-cell therapy for malignant tumorsMalignant tumorJPRN-UMIN000004610Kanazawa university600
已完成
不适用
Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.JPRN-UMIN000008046Seta Clinic Group20
已完成
不适用
Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapyMalignant tumor (all HLA types)JPRN-UMIN000009447Seta Clinic Group5
招募中
不适用
Prospective clinical investigation of the effects of bariatric surgery on nocturnal hypoxaemic burden in patients with severe obesityE66.02G47.9Sleep disorder, unspecifiedDRKS00026004Klinikum Saarbrücken100